Free whitepaper: Integrated RNA-Seq Data Analysis Pipeline – Generating Evidence-Backed Hypotheses in Silico

Download the free white paper from Ingenuity to see how IPA and CLC bio can help with in silico analysis of RNA-Seq data to identify patient-specific prostate cancer mechanisms, potential biomarkers, and to generate evidence-backed hypotheses. You can also register for an upcoming webinar on November 2 to see how to use IPA to analyze Illumina RNA-Seq data to get a better understanding of biological signatures relevant to Alzheimer’s disease.

You can download the free white paper by clicking here.

Translating disease research into personalized medicine is the promise of next generation sequencing.  However, it comes with a host of problems, including overwhelming amounts of data and a huge challenge in translating that data back to implicated biology.  Successful NGS data analysis clearly requires a biological analysis component – the ability to get translate large amounts of data into better insights into disease phenotypes that can yield clinically actionable hypotheses.

Download the white paper to explore this approach in more detail.  Here we use a prostate adenocarcinoma dataset as an example, with a goal of using an in silico approach to explore patient-specific prostate cancer mechanisms and possible clinical biomarkers.  The goal of this study was to get novel insights into the mechanisms of disease by leveraging the rapidly growing next generation sequencing (NGS) data, and in particular, human transcriptome data through in silico data analysis and interpretation using IPA and CLC bio. The analysis of altered expression of genes and regulatory regions can pinpoint specific pathways and processes activated in growing cancer cells within tumors. IPA helped determine these activated pathways and networks and shed light on dysregulated processes, informed treatment options and highlighted potential biomarkers to further the ultimate goal to improve patient prognosis and treatment.You’ll see how this approach can help you:

  • Pinpoint specific pathways and processes activated in growing cancer cells within tumors
  • More easily identify affected processes
  • Determine treatment options on a patient-specific basis
  • Identify potential biomarkers in order to improve patient treatment and prognosis
  • Generate plausible in silico hypotheses related to individual patient’s mechanisms of disease
  • Use NGS data both for clinical insights as well as clinical research

You can download the free white paper by clicking here.

To learn more about using IPA for RNA-Seq data, you can register for our November 2 webinar: Alzheimer’s Disease and NGS – Using IPA to analyze Illumina RNA-Seq data reveals abundance-specific biological signatures